{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:29:19Z","timestamp":1777577359025,"version":"3.51.4"},"reference-count":52,"publisher":"American Society for Microbiology","issue":"18","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"HHS | U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["Z01 BK 04010-11 LHV\/0459"],"award-info":[{"award-number":["Z01 BK 04010-11 LHV\/0459"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2022,9,28]]},"abstract":"<jats:p>Vaccine efficacy and immunity to viral infection are often measured by neutralizing antibody titers. T cells are specialized subsets of immune cells with antiviral activity, but this response is variable and difficult to track.<\/jats:p>","DOI":"10.1128\/jvi.01166-21","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T13:01:12Z","timestamp":1662555672000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1,"title":["Enhanced<i>In Vitro<\/i>and<i>In Vivo<\/i>Potency of a T Cell Epitope in the Ebola Virus Glycoprotein Following Amino Acid Replacement at HLA-A*02:01 Binding Positions"],"prefix":"10.1128","volume":"96","author":[{"given":"Sylvie","family":"Chabot","sequence":"first","affiliation":[{"name":"Division of Viral Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusra","family":"Gimie","sequence":"additional","affiliation":[{"name":"Division of Viral Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karam","family":"Obeid","sequence":"additional","affiliation":[{"name":"Division of Viral Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaekwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Viral Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clement A.","family":"Meseda","sequence":"additional","affiliation":[{"name":"Division of Viral Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishnamurthy","family":"Konduru","sequence":"additional","affiliation":[{"name":"Division of Emerging Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Division of Emerging Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Sheng Fowler","sequence":"additional","affiliation":[{"name":"Division of Viral Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry P.","family":"Weir","sequence":"additional","affiliation":[{"name":"Division of Viral Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Peden","sequence":"additional","affiliation":[{"name":"Division of Viral Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0874-359X","authenticated-orcid":true,"given":"Marian E.","family":"Major","sequence":"additional","affiliation":[{"name":"Division of Viral Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"World Health Organization. 2016. Situation report. Ebola virus disease. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/208883\/ebolasitrep_10Jun2016_eng.pdf?sequence=1. Accessed May 17 2019."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2016.0123"},{"key":"e_1_3_3_4_2","unstructured":"Centers for Disease Control and Prevention C. 2021. History of Ebola virus disease (EVD) outbreaks. https:\/\/www.cdc.gov\/vhf\/ebola\/history\/chronology.html. Accessed August 29 2022."},{"key":"e_1_3_3_5_2","unstructured":"U.S. Food and Drug Administration. December 19 2019. First FDA-approved vaccine for the prevention of Ebola virus disease marking a critical milestone in public health preparedness and response. https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health. Accessed August 29 2022."},{"key":"e_1_3_3_6_2","unstructured":"World Health Organization. 2021. Ebola virus disease. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ebola-virus-disease. Accessed August 29 2022."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61117-5"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32621-6"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30165-8"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2016.10.016"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60553-0"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1651140"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411627"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4218"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007564"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.01.113"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162446"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.03.045"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0198-8859(99)00155-x"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.04.034"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20189"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1286-4579(03)00044-3"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.06.087"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302607"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0587-1"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13337-013-0162-z"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa379"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-1759(01)00535-x"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/326881a0"},{"key":"e_1_3_3_30_2","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.4049\/jimmunol.162.7.3915","article-title":"Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes","volume":"162","author":"Ishioka GY","year":"1999","unstructured":"Ishioka GY, Fikes J, Hermanson G, Livingston B, Crimi C, Qin M, del Guercio MF, Oseroff C, Dahlberg C, Alexander J, Chesnut RW, Sette A. 1999. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol 162:3915\u20133925.","journal-title":"J Immunol"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2004.01.006"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7020034"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.2147\/AABC.S115859"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-017-4328-8"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.586595"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.10.105"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1806200115"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30736-2"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3714"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-019-0133-y"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0198-8859(94)00151-F"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400800"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.6.833"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.15.5409"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.019"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.03.033"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/0471142727.mb1616s43"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23712-9"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.14.8828-8834.2005"},{"key":"e_1_3_3_50_2","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.4049\/jimmunol.142.4.1366","article-title":"Cytotoxic T cell responses in HLA-A2.1 transgenic mice. Recognition of HLA alloantigens and utilization of HLA-A2.1 as a restriction element","volume":"142","author":"Le AX","year":"1989","unstructured":"Le AX, Bernhard EJ, Holterman MJ, Strub S, Parham P, Lacy E, Engelhard VH. 1989. Cytotoxic T cell responses in HLA-A2.1 transgenic mice. Recognition of HLA alloantigens and utilization of HLA-A2.1 as a restriction element. J Immunol 142:1366\u20131371.","journal-title":"J Immunol"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301415"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2015.3673"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.14-268094"}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jvi.01166-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jvi.01166-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T10:24:53Z","timestamp":1676715893000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jvi.01166-21"}},"subtitle":[],"editor":[{"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":52,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,9,28]]}},"alternative-id":["10.1128\/jvi.01166-21"],"URL":"https:\/\/doi.org\/10.1128\/jvi.01166-21","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"assertion":[{"value":"2021-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01166-21"}}